| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1048852752 |
| P356 | DOI | 10.1007/S11926-013-0318-2 |
| P8608 | Fatcat ID | release_f6hwldqhd5h3jk47lzwzfgxuo4 |
| P698 | PubMed publication ID | 23494857 |
| P50 | author | Munther A. Khamashta | Q73418907 |
| P2093 | author name string | Sinthiya Punnialingam | |
| P2860 | cites work | A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) | Q28174751 |
| Warfarin, aspirin, or both after myocardial infarction | Q28193836 | ||
| Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment | Q28194379 | ||
| Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals | Q28210153 | ||
| Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals | Q28217805 | ||
| Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment | Q28218361 | ||
| Guidelines on oral anticoagulation with warfarin - fourth edition | Q28240666 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| New anticoagulants | Q75248061 | ||
| Clinical improvement in antiphospholipid syndrome after rituximab therapy | Q82727536 | ||
| Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies | Q83389363 | ||
| Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events | Q85002100 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients | Q33369688 | ||
| Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort | Q33384874 | ||
| Use of rituximab in the antiphospholipid syndrome | Q33389337 | ||
| Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. | Q33518180 | ||
| Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome | Q33630007 | ||
| International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop | Q33685960 | ||
| Antiphospholipid antibodies and the protein C pathway | Q34021296 | ||
| Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34788523 | ||
| Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis | Q34963070 | ||
| Management of the obstetric antiphospholipid syndrome | Q35743192 | ||
| A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies | Q37020336 | ||
| Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome | Q37473270 | ||
| High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. | Q37950724 | ||
| Antiphospohlipid syndrome in obstetrics | Q37955583 | ||
| Intensity and duration of anticoagulation therapy in antiphospholipid syndrome | Q37998986 | ||
| Secondary prevention in thrombotic antiphospholipid syndrome | Q38013589 | ||
| Catastrophic antiphospholipid syndrome (CAPS). | Q38049765 | ||
| Antimalarial agents and lupus. | Q40737191 | ||
| The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. | Q40903111 | ||
| Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice | Q41927420 | ||
| Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). | Q43201516 | ||
| Statins for the treatment of antiphospholipid syndrome? | Q43275855 | ||
| Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients | Q43519903 | ||
| A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome | Q44588720 | ||
| GAPSS: the Global Anti-Phospholipid Syndrome Score | Q44993606 | ||
| Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome | Q47373774 | ||
| A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism | Q49171054 | ||
| Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis | Q49173787 | ||
| Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. | Q53354829 | ||
| Antiphospholipid syndrome | Q55891386 | ||
| The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population | Q61845862 | ||
| Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment | Q68139494 | ||
| Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? | Q68556883 | ||
| Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry | Q71112355 | ||
| A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin | Q71344109 | ||
| Prospective Studies of the Association Between Anticardiolipin Antibody and Outcome of Pregnancy | Q72060395 | ||
| Antiphospholipid antibodies in pregnancy: prevalence and clinical associations | Q72551109 | ||
| The management of thrombosis in the antiphospholipid-antibody syndrome | Q72619159 | ||
| Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients | Q72671950 | ||
| P433 | issue | 4 | |
| P921 | main subject | thrombosis | Q261327 |
| anticoagulation | Q63279445 | ||
| P304 | page(s) | 318 | |
| P577 | publication date | 2013-04-01 | |
| P1433 | published in | Current Rheumatology Reports | Q23930052 |
| P1476 | title | Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop? | |
| P478 | volume | 15 |
| Q33431396 | Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein are Strongly Associated with the Occurrence of Acute Thrombotic Events |
| Q33423959 | Current treatment of antiphospholipid syndrome: lights and shadows |
| Q38180647 | Management of recurrent thrombosis in antiphospholipid syndrome |
| Q49968681 | Mechanisms and management of thrombosis and bleeding in antiphospholipid syndrome |
| Q35308972 | Treatment of the antiphospholipid syndrome |
Search more.